nostrum Pipelines
nostrum Pipelines
OMNES 5 probatae sunt suggestae technologiae technologiae vaccinae, una cum quolibet productum vaccinum commercium vel in
progressus
Viral vaccina
Rabies
Serum liberum Rabies VaccineGlobally primo-in-genus
Progredior:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approbatio
√
Iterative-processus valde efficax HDC Rabies VaccineIn domo R&D
Progredior:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approbatio
√
Influenza
Quadrivalent Influenza Virus Vaccine (MDCK Cellae)Domestice primo-in-genus
Progredior:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approbatio
√
HFMD
EV71-CA16 HFMD Vaccine (HDC)Globally primo-in-genus
Progredior:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approbatio
√
variant vaccina
Rabies
Iterative variant Rabies VaccineGlobally primo-in-genus
Progredior:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approbatio
√
robusteis
variant musculo VaccineDomestice primo-in-genus IND approbatione (in China & US)
Progredior:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approbatio
√
RSV
mRNA RSV VaccineDomestice primo-in-genus IND approbatione (in China & US)
Progredior:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approbatio
√
Influenza
mRNA Influenza VaccineGlobally primo-in-genus
Progredior:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approbatio
√
Bacterial vaccina
Peripneumonia
Pneumococcale vaccinum 13-valens (PCV13)In domo R&D
Progredior:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approbatio
√
20-Valent Pneumococcal Vaccine Conjugate (PCV20)Domestice primo-in-genus
Progredior:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approbatio
√
24-Valent Pneumococcal Vaccine Conjugate (PCV24)Globally primo-in-genus
Progredior:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approbatio
√
23-valent Pneumococcal Polysaccharide Vaccine (PPSV23)In domo R&D
Progredior:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approbatio
√
Meningococcal
Group ACYW135 Meningococcal Conjugate Vaccine (MCV4)In domo R&D
Progredior:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approbatio
√
Hexavalent Meningococcal VaccineGlobally primo-in-genus
Progredior:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approbatio
√
Group B Strp
Hexavalent Group B Streptococcus Conjugate VaccineGlobally primo-in-genus
Progredior:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approbatio
√
Tetanus
Absorbuit Tetanus VaccineIn domo R&D
Progredior:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approbatio
√
Hib
Hib Conjugate VaccineIn domo R&D
Progredior:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approbatio
√
Compositum vaccinum
DTcP-Hib-Mcv4In domo R&D
Progredior:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approbatio
√
Diphtheria, tetanus et pertussis (acellularia, partium) vaccinum (DTcP)In domo R&D
Progredior:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approbatio
√
Genus machinatum vaccina
Vaccinum genere machinatum
Recombinant Group B Meningococcal VaccineIn domo R&D
Progredior:
Preclinical
√
IND
√
Phase I
√
Phase II
√
Phase III
√
NDA & Approbatio
√
AI structuram antigenam et seriem vaccinorum variante designare adhibetur, et etiam conamur uti
AI to
adiuvaret in processu vaccini R&D. In futurum exspectamus ut profunditatem applicationum exsistentium augeamus
et expand eius
applicatio in clinicis iudicii analysi.
